Log in

Start Your Membership Now

On May 2, 2017, Harvard Pilgrim Health Care (HPHC) and Amgen, Inc. (Amgen) announced that they had reached an agreement on a value-based purchasing agreement for the cholesterol drug Repatha. In the agreement, Amgen will refund the cost of the drug for any eligible consumer who experiences a resulting heart attack or stroke while on Repatha for six months or more while maintaining appropriate compliance on the drug.

Repatha is intended for individuals at high risk for cardiovascular diseases who are not able to adequately control their low-density lipoprotein (LDL-C) levels (bad cholesterol) through dietary changes and . . .

Want To Read More? Log In Or Become A Paid Member
Resource Available For Paid OPEN MINDS Circle Members Only
Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!
Log In
If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

Become A Paid Member
If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.

Tagged As: